EPI-321

· Epicrispr Biotechnologies, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for EPI-321, covering 2026-04-22 to 2026-04-22. Get the full timeline:

Most recent: Clinical Trial Update: A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy [Phase 1, Phase 2]